Video

Dr Epstein-Peterson on the Use of CAR T-Cell Therapy in MCL

Zachary Epstein-Peterson, MD, discusses the use of CAR T-cell therapy in mantle cell lymphoma and highlights questions that remain to be answered within the treatment landscape.

Zachary Epstein-Peterson, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapy in mantle cell lymphoma (MCL) and highlights questions that remain to be answered within the treatment landscape.

Clinicians and patients alike are in a golden age of therapy for treating patients with MCL, Epstein-Peterson begins. However, historically, the outcomes for patients with the disease are very poor, specifically in patients with relapsed/refractory disease, Epstein-Peterson notes, adding that despite this, there are now many new tools in a treating clinician’s treatment armamentarium, most of which he says are effective and tolerable. Overall, it is a promising time to help care for patients with the disease and assist in pioneering new treatments for the future, Epstein-Peterson adds.

Looking to the future of beneficial treatments for this patient population, the landscape is likely to include CAR T-cell therapies, Epstein-Peterson continues. CAR T cells are firmly established in the care of patients with diffuse large B-cell lymphoma, but not as much in the care of patients with MCL, Epstein-Peterson adds. Based on the data seen from treatment with brexucabtagene autoleucel (brexu-cel; Tecartus) and lisocabtagene maraleucel (liso-cel; Breyanzi), these therapies work well in treating patients with MCL, though there are differing toxicity profiles between the 2 regimens. Despite the associated adverse events, the therapies remain manageable, Epstein-Peterson notes.

It remains vital to be aware of cytokine release syndrome and of neurotoxicity in patients, though this does not deter from the agents’ efficacy, Epstein-Peterson adds. Investigators will continue to investigate the optimal patient population to be treated with CAR T-cell therapies and how the CAR T-cell treatments can be best sequenced with one another in the relapsed/refractory setting, Epstein-Peterson explains. Ultimately, clinicians will need to address toxicities more effectively moving forward, but the data from CAR T-cell therapy to date in MCL are encouraging, Epstein-Peterson concludes.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD